International Regulators Agree On Foundations For Postmarket Clinical Studies
Executive Summary
A new document from the IMDRF outlines the conditions for when postmarket clinical follow-up studies may be necessary, but underscores they have to conform to their local regulatory regimes.
You may also be interested in...
Two Draft Guidances Set Up FDA’s Plans To Gather Postmarket Data
The guidance documents outline the statutory authority the US FDA has in requiring postmarket surveillance reports and studies, the real-world evidence it plans to ask for from sponsors, and administrative details that may be expected.
Massive Family Dollar Rat Infestation Leads To Multi-State Recall
The US FDA found more than 2,000 rats at an Arkansas Family Dollar distribution center, leadingto a six-state recall for products including feminine hygiene products, contact lens cleaners and face masks.
Digital Health Roundup: Exec Chats With Illumina, Bloom, AngelMed; M&A, Funding; FDA Down-Classifies Apps
In this roundup feature focusing on new developments in digital health, Medtech Insight spotlights IBM Watson Health’s divestiture and other financing news, Exec Chats with Illumina, AngelMed and Bloom, Philips’ new hand-held ultrasound device and autonomous robotic surgery, as well as the latest FDA news on digital health.